Publications by authors named "Deepa Subramaniam"

Claim this Profile
R
Recasting of Periodontal Diagnosis.
Deepa Subramaniam, Bhumimathan Swamikannu, R Narasimha Raghavan, V Keshavan, Karthikeyan P Rajendran

J Pharm Bioallied Sci· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biphasic Calcium Phosphate in the Extraction Socket Preservation: A Systematic Review.
S Mohanasatheesh, Anitha Balaji, Deepa Subramaniam, Vishnu Ganapathy, Karthikeyan P Rajendran

J Pharm Bioallied Sci· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors.
Rachel E Sanborn, Michael J Pishvaian, Margaret K Callahan, Amy Weise, Branimir I Sikic, Deepa S Subramaniam

J Immunother Cancer· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Trial of Dasatinib and Osimertinib in TKI Naïve Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer.
Chul Kim, Stephen V Liu, Jennifer Crawford, Tisdrey Torres, Vincent Chen, Deepa S Subramaniam

Front Oncol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1 Activated T Cells.
Simon J Dovedi, Matthew J Elder, Chunning Yang, Suzanne I Sitnikova, Lorraine Irving, Deepa S Subramaniam

Cancer Discov· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment with pembrolizumab in programmed death ligand 1-positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE-028 trial.
David A Reardon, Tae Min Kim, Jean-Sebastien Frenel, Matteo Simonelli, Juanita Lopez, Deepa S Subramaniam

Cancer· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world impact of brain metastases on healthcare utilization and costs in patients with non-small cell lung cancer treated with EGFR-TKIs in the US.
Amanda M Kong, Melissa Pavilack, Hairong Huo, Rahul Shenolikar, Meghan Moynihan, Deepa S Subramaniam

J Med Econ· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I trial of the mTOR inhibitor temsirolimus in combination with capecitabine in patients with advanced malignancies.
Neel D Trivedi, Samantha Armstrong, Hongkun Wang, Marion Hartley, John Deeken, Deepa Subramaniam

Cancer Med· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of the Lu-DOTA-Tyr-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung.
Chul Kim, Stephen V Liu, Deepa S Subramaniam, Tisdrey Torres, Massimo Loda

J Immunother Cancer· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Electromagnetic fields alter the motility of metastatic breast cancer cells.
Ayush Arpit Garg, Travis H Jones, Sarah M Moss, Sanjay Mishra, Kirti Kaul, Deepa Subramaniam, Vish V Subramaniam

Commun Biol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased infection rates associated with tetracycline therapy given for epidermal growth factor receptor inhibitor (EGFRI)-associated acneiform eruption: A retrospective study of data from two cancer centers.
Michele Z Magnino, David J Perry, Deepa S Subramaniam, Cynthia M C DeKlotz

J Am Acad Dermatol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implementation of the Smoking Treatment and Recovery (STAR) program: healthy cancer survivorship through integrated tobacco control.
Kathryn L Taylor, Shelby Fallon, Deepa Subramaniam, Kimberly Davis, Chan To

J Cancer Surviv· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignancies.
Filipa Lynce, Hongkun Wang, Emanuel F Petricoin, Paula R Pohlmann, Brandon Smaglo, Deepa S Subramaniam

Cancer Chemother Pharmacol· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identifying Resistance Mechanisms to Osimertinib via Blood Biopsy.
Michael J Jelinek, Samantha A Armstrong, Jyoti D Patel, Deepa S Subramaniam

Clin Lung Cancer· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Activity of Nivolumab for Human Papilloma Virus-Related Juvenile-Onset Recurrent Respiratory Papillomatosis.
Ben C Creelan, M Usman Ahmad, Frank J Kaszuba, Farah K Khalil, Allison W Welsh, Deepa S Subramaniam

Oncologist· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC): an update.
Sushma Jonna, Deepa S Subramaniam

Discov Med· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dramatic Response to Sequential BRAF Inhibition in V600E-Mutant Metastatic Lung Adenocarcinoma.
Sushma Jonna, Giuseppe Giaccone, Ross Filice, Jenna Kramer, Deepa S Subramaniam

JCO Precis Oncol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Editorial: Central Nervous System Metastases in Lung Cancer Patients: From Prevention to Diagnosis and Treatment.
Lizza E L Hendriks, Deepa S Subramaniam, Anne-Marie C Dingemans

Front Oncol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Outcomes Following Conventionally Fractionated Stereotactic Boost for High-Grade Gliomas in Close Proximity to Critical Organs at Risk.
Michael C Repka, Siyuan Lei, Lloyd Campbell, Simeng Suy, Jean-Marc Voyadzis, Deepa S Subramaniam

Front Oncol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Understanding molecular diagnostic technology in oncology through the lens of lung cancer.
Sushma Jonna, Giuseppe Giaccone, Deepa S Subramaniam

Discov Med· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer.
William J Kelly, Neil J Shah, Deepa S Subramaniam

Front Oncol· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas.
Sherise D Ferguson, Shouhao Zhou, Jason T Huse, John F de Groot, Joanne Xiu, Deepa S Subramaniam

J Neuropathol Exp Neurol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours.
Jordan Berlin, Ramesh K Ramanathan, John H Strickler, Deepa S Subramaniam, John Marshall

Br J Cancer· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.
David E Gerber, Mark A Socinski, Joel W Neal, Heather A Wakelee, Keisuke Shirai, Deepa S Subramaniam

Lung Cancer· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase Ib/II Study of Ganetespib With Doxorubicin in Advanced Solid Tumors Including Relapsed-Refractory Small Cell Lung Cancer.
Deepa S Subramaniam, Stephen V Liu, Jeanette Crawford, Jenna Kramer, Jillian Thompson

Front Oncol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis